The IcoCell cell line development platform generates stable biopharmaceutical CHO high-producer protein and antibody clones with competitive titers and timelines. It is fully embedded into our integrated in-house discovery and development capabilities, including analytical and downstream processing expertise, effectively speeding up our clients’ clinical development timelines and de-risking their clinical development projects.
Why choose IcoCell for stable GMP compatible cell line?
HIGH PRODUCTIVITY
HIGH PRODUCTIVITY
Our proven cell line development workflow yields stable biopharmaceutical CHO cell lines with up to 10 g/l production titers for recombinant antibodies and proteins.
RAPID TIMELINES
RAPID TIMELINES
Our optimized CHO cell line development process yields stable producer clone pools already week after CLD starts.
PURE FEE FOR SERVICE
PURE FEE FOR SERVICE
No clinical milestone payments, no royalties – only fee for service.
99.9% MONOCLONAL ASSURANCE
99.9% MONOCLONAL ASSURANCE
In our IcoCell platform we employ the VIPS™ In-Situ Plate Seeding to assure 99.9% monoclonality. The "double lock" method, that combines post cell-dispensing imaging and analysis with daily outgrowth imaging for later regulatory submission.
GMP- COMPATIBLE DOCUMENTATION
GMP- COMPATIBLE DOCUMENTATION
Full documentation in form of a cell line development report is provided, which is essential for later regulatory submission and GMP manufacturing.
COMPREHENSIVE ANALYTICS
COMPREHENSIVE ANALYTICS
The IcoCell cell line development
approach follows a rigorous analytical regimen with ever-increasing stringency along the way, both on the product and cellular level.
Cell line development workflow with IcoCell
Early non-GMP protein production from stable CHO producer clone pools
A streamlined clone pool selection approach was developed to efficiently generate near-homogenous stable CHO production clone pools with high target protein productivity. These clone pools readily allow gram-scale production runs, plus rapid product characterization, analytical development, formulation development, in vivo POC studies etc.
COST EFFECTIVE
COST EFFECTIVE AND ROYALTY FREE
We only charge a fee for service.
HIGH TITERS
HIGH TITERS
High titers of recombinant protein is achieved by inserting transgene into transcriptionally active genomic regions.
PROJECT DE-RISKING
PROJECT DE-RISKING
Early material from stable producer clone pools is the first stage at which one can obtain tangible purified recombinant material that allows an initial peek on the later clone-derived protein. This material can be tested for activity in vitro and even in vivo, and several project-accelerating activities (such as analytical and formulation development) can be started ahead of time.
IcoCell minipools can be used to produce material for early proof of concept and non-GLP tox studies. Also for IVD assays.
EARLY PROOF OF CONCEPT
EARLY PROOF OF CONCEPT
Stable producer clone pool titers convey a robust indication of the expected productivities of the final clones, and allow e.g. early proof of concept in vivo in non-GLP toxicology studies, to re-confirm the clinical candidates' potential.